Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia
作者: Joseph A. JakubowskiCarolyn C. HoppeChunmei ZhouBrendan E. SmithPatricia B. BrownLori E. HeathBaba InusaDavid C. ReesDavid S. SmallNeehar GuptaSuqin YaoMatthew HeeneyJulie Kanter
作者单位: 1Joseph A. Jakubowski, PhD, Eli Lilly and Company, Indianapolis, IN 46285, USA, Tel.: +1 317 276 9036, Fax: +1 317 433 1996, E-mail:
刊名: Thromb Haemost, 2017, Vol.117 (3), pp.580-588
来源数据库: Schattauer GmbH
DOI: 10.1160/TH16-09-0731
关键词: PrasugrelVerifyNowplateletsclinical trialantiplatelet
原始语种摘要: Patients with sickle cell anaemia (SCA) have vaso-occlusive crises resulting from occlusive hypoxic-ischaemic injury. Prasugrel inhibits platelet activation and aggregation involved in SCA pathophysiology. Determining Effects of Platelet Inhibition on Vaso-Occlusive Events (DOVE) was a phase 3, double-blind, randomised, placebo-controlled trial assessing prasugrel efficacy. DOVE sought to bring patients’ P2Y12 reaction unit (PRU) value within a targeted range via prasugrel dose adjustments using encrypted VerifyNow P2Y12® (VN-P2Y12) point-of-care testing and an interactive voice-response system (IVRS). After PRU determination, randomised patients received 0.08 mg/kg/day prasugrel or placebo. Encrypted PRUs and IVRS provided double-blind dose adjustments to achieve a...
全文获取路径: Schattauer 出版社 
影响因子:6.094 (2012)

  • double 双重的
  • point 
  • range 射程
  • adjust 
  • blind 暗的
  • sickle 切割器镰刀
  • platelet 血小板
  • higher 
  • values 价值观
  • anaemia 贫血